What is the address of PHARMARE?

The registered office of PHARMARE is located at Kardinaal Mercierlaan 30, 8420 De Haan.

Is PHARMARE still active?

Yes. According to the CBE (31 October 2026) PHARMARE is active, legal situation “Normale toestand”, started on 10 June 2014.

Is PHARMARE registered on Peppol?

Yes, PHARMARE is registered on the Peppol network with ID 0208:0553716481.

What is the enterprise number of PHARMARE?

The enterprise number of PHARMARE is BE0553716481.

When was PHARMARE founded?

PHARMARE was founded on 10 June 2014.

Who are the directors of PHARMARE?

According to the 2025 annual accounts, the directors of PHARMARE are: Soetkin Op de Beéck.

Is PHARMARE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 10 June 2014; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PHARMARE make in 2025?

PHARMARE posted a profit after taxes of € 161,633 in financial year 2025.

What is the revenue of PHARMARE?

As a small company, PHARMARE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 279,696.

Does PHARMARE have a website?

Yes, PHARMARE has a website at wenduinepharma.be.

PHARMARE (Private Limited) - De Haan - BE0553716481

Q: What does PHARMARE do?

PHARMARE is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 10 June 2014, 1 establishment.

Dossier PHARMARE, printed on 31 October 2026 from databakkes.be/en/0553716481/pharmare. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 49 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

PHARMARE from De Haan, company number BE0553716481, closed financial year 2025 with a result of € 161,633 after tax. For that financial year PHARMARE recorded a gross margin of € 279,696 and equity of € 578,365. Compared with financial year 2024, the result moved from € 87,407 to € 161,633. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on November 27, 2025.

What it is worth Growing

€ 578,365

▲ 25% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 161,633

▲ 85% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 47,686

▼ 82% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 47,400 paid out

29 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 44,619

▼ 24% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 7 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 640,774

▼ 15% vs 2024

€ 94,463 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.

Owed to suppliers

€ 8,859

▲ 22% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 28,649

▲ 8% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 487,879 Gross margin 2022: € 487,879 First fiscal year in the series	€ 200,700 Gross margin 2023: € 200,700 ▼ 59% vs 2022 (€ 487,879) Unfavourable step	€ 205,249 Gross margin 2024: € 205,249 ▲ 2% vs 2023 (€ 200,700) Favourable step	€ 279,696 Gross margin 2025: € 279,696 ▲ 36% vs 2024 (€ 205,249) Favourable step	▲ 36%
Profit after taxes	€ 264,551 Profit after taxes 2022: € 264,551 First fiscal year in the series	€ 55,324 Profit after taxes 2023: € 55,324 ▼ 79% vs 2022 (€ 264,551) Unfavourable step	€ 87,407 Profit after taxes 2024: € 87,407 ▲ 58% vs 2023 (€ 55,324) Favourable step	€ 161,633 Profit after taxes 2025: € 161,633 ▲ 85% vs 2024 (€ 87,407) Favourable step	▲ 85%
Equity	€ 543,402 Equity 2022: € 543,402 First fiscal year in the series	€ 598,726 Equity 2023: € 598,726 ▲ 10% vs 2022 (€ 543,402) Favourable step	€ 464,132 Equity 2024: € 464,132 ▼ 22% vs 2023 (€ 598,726) Unfavourable step	€ 578,365 Equity 2025: € 578,365 ▲ 25% vs 2024 (€ 464,132) Favourable step	▲ 25%
Total debts	€ 1,163,559 Total debts 2022: € 1,163,559 First fiscal year in the series	€ 1,318,214 Total debts 2023: € 1,318,214 ▲ 13% vs 2022 (€ 1,163,559) Unfavourable step	€ 1,015,064 Total debts 2024: € 1,015,064 ▼ 23% vs 2023 (€ 1,318,214) Favourable step	€ 709,476 Total debts 2025: € 709,476 ▼ 30% vs 2024 (€ 1,015,064) Favourable step	▼ 30%
Cash	€ 20,979 Cash 2022: € 20,979 First fiscal year in the series	€ 12,951 Cash 2023: € 12,951 ▼ 38% vs 2022 (€ 20,979) Unfavourable step	€ 262,495 Cash 2024: € 262,495 ▲ € 249,544 vs 2023 (€ 12,951) Favourable step	€ 47,686 Cash 2025: € 47,686 ▼ 82% vs 2024 (€ 262,495) Unfavourable step	▼ 82%
Land & buildings	€ 84,182 Land & buildings 2022: € 84,182 First fiscal year in the series	€ 83,704 Land & buildings 2023: € 83,704 ▼ 1% vs 2022 (€ 84,182) Unchanged	€ 83,225 Land & buildings 2024: € 83,225 ▼ 1% vs 2023 (€ 83,704) Unchanged	€ 102,727 Land & buildings 2025: € 102,727 ▲ 23% vs 2024 (€ 83,225) Unchanged	▲ 23%
Retained profit	€ 533,402 Retained profit 2022: € 533,402 First fiscal year in the series	€ 588,726 Retained profit 2023: € 588,726 ▲ 10% vs 2022 (€ 533,402) Favourable step	€ 439,132 Retained profit 2024: € 439,132 ▼ 25% vs 2023 (€ 588,726) Unfavourable step	€ 553,365 Retained profit 2025: € 553,365 ▲ 26% vs 2024 (€ 439,132) Favourable step	▲ 26%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 237,000 Dividend 2024: € 237,000 Unchanged (€ 0) Unchanged	€ 47,400 Dividend 2025: € 47,400 ▼ 80% vs 2024 (€ 237,000) Unchanged	▼ 80%
Bank debt	€ 1,095,050 Bank debt 2022: € 1,095,050 First fiscal year in the series	€ 1,159,561 Bank debt 2023: € 1,159,561 ▲ 6% vs 2022 (€ 1,095,050) Unfavourable step	€ 757,775 Bank debt 2024: € 757,775 ▼ 35% vs 2023 (€ 1,159,561) Favourable step	€ 640,774 Bank debt 2025: € 640,774 ▼ 15% vs 2024 (€ 757,775) Favourable step	▼ 15%
Balance sheet total	€ 1,706,961 Balance sheet total 2022: € 1,706,961 First fiscal year in the series	€ 1,916,940 Balance sheet total 2023: € 1,916,940 ▲ 12% vs 2022 (€ 1,706,961) Unchanged	€ 1,479,197 Balance sheet total 2024: € 1,479,197 ▼ 23% vs 2023 (€ 1,916,940) Unchanged	€ 1,287,841 Balance sheet total 2025: € 1,287,841 ▼ 13% vs 2024 (€ 1,479,197) Unchanged	▼ 13%

Key figures of PHARMARE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2026 has not been filed yet; it was expected before 31 October 2026.

What happened to PHARMARE?

What happened at PHARMARE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Nov 27, 2025 New annual accounts for financial year 2025: profit of € 161,633 (▲ 85% vs 2024). filed late Source: NBB ↗
Jun 10, 2014 New establishment in De Haan. KBO
Jun 10, 2014 Start of the company according to the CBE. KBO

In short

From € 264,551 profit in 2022 to € 161,633 profit in 2025.

Paid € 216,879 in corporate taxes since 2022.

Best year ever: 2022, with € 264,551 profit.

Paid out € 284,400 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Soetkin Op de Beéck

PHARMARE

Apotheek Soetkin Op de Beéck 100%

Behind PHARMARE is Soetkin Op de Beéck. It owns 100% of Apotheek Soetkin Op de Beéck itself.

Directors

According to the 2025 annual accounts

Soetkin Op de Beéck

Director

Also active at: Apotheek Soetkin Op De Beeck

Establishments

Establishment units

Physical locations of this company

Registered office

Kardinaal Mercierlaan 30

8420 De Haan

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS wenduinepharma.be

About

Technologies

AMPAdobe FontsAlpine.jsCookie ConsentGoogle FontsGoogle TranslateNginxPHPPlausibleVimeoYouTube EmbedreCAPTCHA

Hosting & Email

Email provider

Microsoft 365

Hosting

UPCLOUD, FI

Website info

HTTPS Ja

Indexable pages 110,258

Languages FR, NL

Features

Webshop Newsletter Contact page

Security

✓ HTTPS

✓ SPF

✗ DMARC

Network

✓ IPv6

Details

Company number

0553.716.481

VAT number

BE 0553.716.481

Registered office

Kardinaal Mercierlaan 30, 8420 De Haan

Names & denominations

PHARMARE

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

10 June 2014

Peppol

Active · Active since 1 Jan 2001

Contact

wenduinepharma.be

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMARE

Warning lights

Financials

What happened to PHARMARE?

Management

Directors

Establishments

Establishment units

Website

Technologies

Hosting & Email

Website info

Features

Security

Network

Details

Frequently asked questions